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Cytochrome P450 enzymes (Cyt. P450s) play a key role in
the synthesis of essential biomolecules, the metabolism of
pharmaceutical drugs, and the detoxification of xenobiotics.
The most ubiquitous form of Cyt. P450s are monooxygenases,
which hydroxylate substrates following the reaction:[1]
R-HþO2 þNADðPÞHþHþ ! R-OHþNADðPÞþ þH2O ð1Þ
The active sites of Cyt. P450s contain a single heme b cofactor
with a proximal cysteinate ligand. Figure 1 shows the active
site of P. putida Cyt. P450cam as an example. The catalytic
mechanism of Cyt. P450s has been studied in detail and is
depicted in Figure 1.[1] After one-electron reduction of the
heme, O2 is bound first and subsequently reduced and
protonated, generating an FeIII–OOH complex (Com-
pound 0). Protonation of this species results in heterolytic
OO bond cleavage, producing the critical intermediate
Compound I and H2O. Compound I is able to abstract
a hydrogen atom from the substrate resulting in an FeIV–
OH complex (Compound II) and a carbon-based substrate
radical, according to the “rebound” mechanism.[1,2c] The
carbon-based radical is finally hydroxylated to complete the
catalytic cycle.
Although Cyt. P450 enzymes have been studied for the
past 56 years, key questions have remained with respect to the
nature of Compound I, its ability to oxidize substrates, and
the role of the proximal thiolate ligand for catalysis. Progress
in this regard has been stalled by the difficulty in trapping
Compound I, which is usually short-lived and generated only
in low yield.[2a,b] Recently, however, Green and co-workers
obtained Compound I in high yield ( 75%) for the first time
by reacting a thermophilic Cyt. P450 (CYP119) in its ferric
oxidation state with meta-chloroperoxybenzoic acid (m-
CPBA).[3a] The UV/Vis spectrum of this species, which is
stable in solution for roughly 35 ms, exhibits the Soret band at
367 nm and Q bands at 610 and 690 nm (Figure 2). Rapid-
freeze quench Mçssbauer spectroscopy of this intermediate
shows isomer shifts and quadrupole splitting values (d=
0.11 mms1 and DEQ= 0.90 mms
1) similar to those of
Compound I of chloroperoxidase (CPO),[4] confirming the
FeIV oxidation state of iron. The EPR spectrum of Com-
pound I exhibits g? values of 1.86 and 1.96 and gk= 2.0, which
is indicative of an S= 1=2 system. This suggests that the Fe
IV=O
unit (S= 1) in this species is antiferromagnetically coupled to
the porphyrin-based radical (S= 1=2), leading to a doublet (S=
1=2) ground state for Compound I.
[3a] These findings are in
agreement with the results of DFT and QM/MM calcula-
tions.[5]
Figure 1. Top: O2 bound to the ferrous heme in the active site of
Cyt. P450cam from P. putida (PDB code 1DZ9). Bottom: The catalytic
cycle of Cyt. P450 monooxygenases (where R–H is the substrate).
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After reaction of Compound I with a substrate having
a CH bond, an FeIV–OH intermediate, Compound II, is
created (see Figure 1). Green and co-workers stabilized this
intermediate using a unique Cyt. P450 (CYP158) that has
a large, solvent-exposed active site.[3b] The FeIV–OH complex
was generated in greater than 90% yield (at pH 9; decaying at
 0.01 s1) by the reaction of the ferric heme protein with m-
CPBA. The UV/Vis spectrum of Compound II has a split
Soret band at 370 and 426 nm and Q bands at 532 and 565 nm,
which is indicative of a six-coordinate (6C) thiolate-ligated
ferryl heme complex. The Mçssbauer spectrum of this
intermediate shows isomer shifts and quadrupole splittings
(d= 0.1 mms1 and DEQ= 2.05 mms
1) similar to those of
Compound II of CPO.[6] Additionally, iron K-edge X-ray
absorption measurements further confirmed that Compound
II is 6C and, importantly, that the iron center is in the ferryl
oxidation state.[3b] These results demonstrate again (in agree-
ment with previous studies) that Compound II in heme-
thiolate active sites is protonated at physiological pH.[3b,6]
The radical rebound-type mechanism described above
requires H-atom abstraction by the metal–oxo unit. Mayer
and co-workers have used linear free energy relationships to
understand H-atom abstraction in metal–oxo systems.[7] It was
shown that the driving force for CH bond activation (DGp) is
related to the energy difference between the OH bond
formed,D(O-H), and the CH bond broken,D(C-H): DGp=
D(C-H)D(O-H).
For heme enzymes, D(O-H) is dependent on the one-
electron reduction potential of Compound I and the pKa of
Compound II as shown in Equation (2) (where C is a con-
stant).[7] In other words, the thermodynamic driving force for
H-atom abstraction can originate from the redox potential or
the basicity of the site, or a combination of both.
DðOHÞ ¼ 23:06EComp-I þ 1:37 pKaComp-II þ C ðkcalmol1Þ ð2Þ
The reduction potential of the heme is largely dictated by
the proximal ligand. For example, it was previously shown
that a thiolate ligand can decrease the FeII/FeIII redox
potential by up to 400 mV compared to that of histidine-
ligated proteins.[1] This suggests that thiolate ligation actually
reduces the driving force for C–H activation that originates
from the redox potential in Compound I. To understand how
Equation (2) applies to CH bond activation by Compound I
in Cyt. P450s, Green and co-workers undertook the tedious
task of determining the basicity of Compound II by system-
atic pH variation [Eq. (3)].
½FeðPorphÞðCysÞðOHÞ þ Base! ½FeðPorphÞðCysÞðOÞ þH½Baseþ
ð3Þ
The deprotonated FeIV=O complex is formed at roughly
pH 14 and retains its thiolate ligand, which is confirmed by
UV/Vis and Mçssbauer spectroscopy (Figure 3). From these
experiments, the pKa of the Fe
IV–OH complex is estimated to
be approximately 12.[3b] Interestingly, this is about 9 times
more basic than Compound II in histidine-ligated proteins
(pKa 3.5).[1] The basicity of Compound II is surprising, since
FeIV=O units are electrophilic and rarely protonated.[4,6] This
emphasizes that the thiolate ligand is a stronger electron
donor than histidine, and in turn makes the FeIV–O unit more
basic. This demonstrates that much of the driving force for C–
H activation by Compound I in Cyt. P450s results from
basicity, and not from a large (positive) redox potential of
this intermediate. In this sense, the thiolate ligand “tames” the
oxidative power of Compound I, without compromising the
driving force for CH bond activation.
Interestingly, this finding parallels observations in
Cyt. P450 nitric oxide reductase (P450nor), an enzyme found
Figure 2. UV/Vis spectrum of ferric Cyt. P450 (black) and spectral
changes upon the addition of m-CPBA (blue, dashed) at different time
points (adapted from reference [3a]). Reprinted with permission from
AAAS.
Figure 3. Top: UV/Vis spectra of Compound II (black) with increasing
pH to form the corresponding FeIV=O complex (red). Bottom: the
same experiment monitored by Mçssbauer spectroscopy (Com-
pound II, blue, FeIV=O, red; adapted from reference [3b]). Reprinted
with permission from AAAS.
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in soil-dwelling fungi and yeast that reduces nitric oxide (NO)
to nitrous oxide (N2O) by the reaction:
2NOþNADðPÞHþHþ ! N2OþNADðPÞþ þH2O ð4Þ
In the proposed mechanism of this enzyme, a ferric heme–
nitrosyl complex reacts with a hydride donor to form an FeII–
NHO species.[8a] In the presence of an axial histidine ligand as
in myoglobin (Mb), the corresponding MbII–NHO adduct is
stable and not further protonated.[9] However, DFT calcu-
lations suggest that the FeII–NHO complex in P450nor is basic
enough to pick up an additional proton, resulting in a doubly
protonated FeIV–NHOH-type species.[8b] The formation of
this intermediate is crucial for P450nor catalysis as it activates
the ferrous HNO complex to react with another molecule of
NO, completing the catalytic cycle. Here, the presence of the
axial thiolate ligand is responsible for the enhanced basicity of
the HNO intermediate in Cyt. P450nor. Hence, in both the
NOR and the monooxygenases, the donation from the
thiolate ligand to the iron center is crucial for catalysis.
In summary, the recent efforts of the Green group in
isolating and characterizing Compounds I and II of
Cyt. P450s have provided key insights into the electronic
structure and reactivity of these important intermediates, and
in this way, have answered key questions with regards to the
mechanism of Cyt. P450s. The high pKa of Compound II
confirms the strong electron-donating nature of the thiolate
ligand and provides the driving force for CH bond activa-
tion. The lowered oxidative power of Compound I in
Cyt. P450s is a means to protect the enzyme from this
reactive intermediate by preventing the fast oxidation of
other amino acids in the proximity of the active site, and in
this way, shutting down nonproductive and potentially
destructive side reactions. In contrast, other heme proteins
such as oxidases and peroxidases, which use Compound I to
oxidize external substrates, are ligated by histidine residues,
leading to a much more oxidizing Compound I, but a much
less basic Compound II. This directly relates to the different
functions of these enzymes. Whereas Cyt. P450s hydroxylate
substrates that are directly bound in the active site, (per)ox-
idases oxidize substrates that in many cases are bound to the
protein surface. Hence, in the latter cases a large driving force
based on a large, positive redox potential is required, whereas
the basicity of Compound IIcannot contribute to reactivity.
This demonstrates again how wisely nature designs its
catalysts, and optimizes the active sites to perfection in order
to mediate a desired reaction.
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